GeneDx Holdings Corp. cash flow to debt ratio of 21.90% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

GeneDx Holdings Corp.'s free cash flow has increased -141.96% from $-33.99M last year to $14.26M, signaling increasing performance

GeneDx Holdings Corp.'s debt to equity ratio is 0.69, which means that the company's assets are unhealthy financed, signaling financial risk.

GeneDx Holdings Corp.'s debt has increased relative to shareholder equity from 0.47 last year to 0.69 today, signaling weakened financials

GeneDx Holdings Corp. has a net cash position, so leverage is healthy.

GeneDx Holdings Corp.'s interest coverage ratio is -20.31, which means that the company struggles to meet interest obligations, signaling financial risk.

GeneDx Holdings Corp.'s profit margin has decreased (36.73%) in the last year from -17.12% to -23.40%, signaling decreasing performance

GeneDx Holdings Corp.'s short-term assets of $268.29M exceed its short-term liabilities of $108.91M

GeneDx Holdings Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

GeneDx Holdings Corp.'s return on equity of -38.72%, is lower than 15.00%, indicating bad performance

GeneDx Holdings Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

GeneDx Holdings Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

GeneDx Holdings Corp. has positive free cash flow, indicating the company generates cash after capital expenditures

GeneDx Holdings Corp. has a free cash flow yield of 0.61%, which is below the 2.00% threshold, indicating limited cash return relative to market value

GeneDx Holdings Corp.'s yearly earnings has increased -59.80% since last year from $-52.29M to $-21.02M, signaling increasing performance

GeneDx Holdings Corp.'s yearly revenue has increased 39.97% since last year from $305.45M to $427.54M, signaling increasing performance

ROIC -14.69% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

GeneDx Holdings Corp.'s 3-year revenue CAGR of 22.13% is positive, indicating growing revenue over the past 3 years

GeneDx Holdings Corp. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

GeneDx Holdings Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

GeneDx Holdings Corp. has insufficient data to evaluate this check.

GeneDx Holdings Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GeneDx Holdings Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

GeneDx Holdings Corp. has an EV/EBITDA ratio of 347.61x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

GeneDx Holdings Corp. has insufficient data to evaluate this check.

GeneDx Holdings Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GeneDx Holdings Corp. has a price-to-book ratio of 9.47x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

GeneDx Holdings Corp. has a price-to-sales ratio of 5.09x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue